Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors
Complete Title: A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients with Targeted Advanced Solid Tumors
Trial Phase: I
Investigator: Michael Schweizer
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors.
Keywords:
- Prostate Cancer, Castration-resistant (CRPC)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Michael Schweizer
RG1122462
NCT05488548
A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients with Targeted Advanced Solid Tumors
Prostate Cancer, Castration-resistant (CRPC)